|
Dec 21
|
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
|
|
Dec 20
|
Merck Provides U.S. Regulatory Update on Gefapixant
|
|
Dec 20
|
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
|
|
Dec 20
|
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
|
|
Dec 19
|
13 Most Promising Growth Stocks According to Analysts
|
|
Dec 19
|
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
|
|
Dec 19
|
Merck gets FDA decision date for new pneumococcal vaccine
|
|
Dec 19
|
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
|
|
Dec 18
|
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
|
|
Dec 18
|
13 Most Profitable Pharmaceutical Stocks Now
|
|
Dec 10
|
12 Dow Stocks Billionaires Like The Most
|
|
Dec 10
|
12 Healthcare Stocks Billionaires Like the Most
|
|
Dec 9
|
Income Investors Should Know That Merck & Co., Inc. (NYSE:MRK) Goes Ex-Dividend Soon
|
|
Dec 8
|
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
|
|
Dec 8
|
Company News for Dec 8, 2023
|
|
Dec 8
|
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
|
|
Dec 8
|
Merck suffers bad week as 3 Keytruda combination trials fail
|
|
Dec 7
|
13 Best S&P 500 Dividend Stocks To Buy
|
|
Dec 7
|
Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study
|
|
Dec 7
|
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
|